financetom
Business
financetom
/
Business
/
Signet Jewelers Fiscal Q1 Adjusted Earnings, Revenue Increase; Fiscal 2026 Outlook Revised
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Signet Jewelers Fiscal Q1 Adjusted Earnings, Revenue Increase; Fiscal 2026 Outlook Revised
Jun 3, 2025 4:50 AM

07:28 AM EDT, 06/03/2025 (MT Newswires) -- Signet Jewelers ( SIG ) reported fiscal Q1 adjusted earnings Tuesday of $1.18 per diluted share, up from $1.11 a year earlier.

Analysts surveyed by FactSet expected $1.00.

Revenue for the quarter ended May 3 was $1.54 billion, up from $1.51 billion a year earlier.

Analysts surveyed by FactSet expected $1.52 billion.

Signet expects fiscal Q2 revenue of $1.47 billion to $1.51 billion. Analysts surveyed by FactSet expect $1.49 billion.

For fiscal 2026, the company now expects adjusted EPS of $7.70 to $9.38, up from the prior forecast of $7.31 to $9.10. Analysts surveyed by FactSet expect $8.31.

Total sales for the fiscal year are now projected to be between $6.57 billion and $6.80 billion, compared with the prior outlook of $6.53 billion to $6.80 billion. Analysts polled by FactSet expect $6.68 billion.

Shares were up more than 12% in recent Tuesday premarket activity.

Price: 75.00, Change: +8.19, Percent Change: +12.26

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PTC Therapeutics Says Phase 2 Votoplam Trial in Huntington's Disease Meets Primary Endpoint
PTC Therapeutics Says Phase 2 Votoplam Trial in Huntington's Disease Meets Primary Endpoint
May 26, 2025
07:56 AM EDT, 05/05/2025 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Monday that a phase 2 study of PTC518, or votoplam, in stage 2 and 3 Huntington's disease met its primary endpoint of reduction in blood Huntingtin protein levels at week 12. The company said the study showed dose-dependent lowering of blood Huntingtin levels, with 23% at the...
Geekco Technologies Extends Private Placement
Geekco Technologies Extends Private Placement
May 26, 2025
07:56 AM EDT, 05/05/2025 (MT Newswires) -- Geekco Technologies ( GKOTF ) over the weekend extended its non-brokered private placement until June 4. The company announced the closing of the first tranche on April 17, and issued around 2.9 million units at $0.05 each for gross proceeds of $149,000 out of a maximum of $400,000 or 8 million units. Each...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Teva, Alvotech Get FDA Approval for Selarsdi's Interchangeablity With Stelara
Teva, Alvotech Get FDA Approval for Selarsdi's Interchangeablity With Stelara
May 26, 2025
07:56 AM EDT, 05/05/2025 (MT Newswires) -- Teva Pharmaceutical (TEVA) and Alvotech ( ALVO ) said Monday that Selarsdi has been approved by the US Food and Drug administration as interchangeable with the reference biologic Stelara. Selarsdi, a human monoclonal antibody that selectively targets the p40 protein, is now interchangeable in all presentations of Stelara, which includes the treatment of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved